Risk factor screening and prediction modeling of gastrointestinal adverse reactions caused by GLP-1RAs

Risk factor screening and prediction modeling of gastrointestinal adverse reactions caused by GLP-1RAs

ObjectiveThis study aimed to explore the risk factors for gastrointestinal side effects (GISEs) in patients with type 2 diabetes mellitus (T2DM) during treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) based on real-world data and to develop a prediction model for GLP-1RA-related G...

Full description

Saved in:

Bibliographic Details
Main Authors:	Rui Gao, Yue Li, Anan Li, Penglin Zhou, Huiying Zong, Yan Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Endocrinology
Subjects:	type 2 diabetes mellitus glucagon-like peptide-1 receptor agonists gastrointestinal side effects risk factors nomogram
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2024.1502050/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clarifying methodological approaches in the assessment of GLP-1 RAs and gastrointestinal cancer risk
by: Gisella Figlioli, et al.
Published: (2024-12-01)

Current and potential use of GLP-1R agonists: beyond type 2 diabetes
by: Graciela Zambrano-Galván, et al.
Published: (2024-10-01)

Adverse effects of GLP – 1 Receptor Agonists
by: Anna Kasprzak, et al.
Published: (2025-02-01)

The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology
by: Sofía Echeverry-Guerrero, et al.
Published: (2024-11-01)

GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges
by: Patrycja Kupnicka, et al.
Published: (2024-11-01)

Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database
by: Samuel Prince Osei, et al.
Published: (2024-12-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks
by: Ioannis Ilias, et al.
Published: (2025-01-01)

Extensive Deep Vein Thrombosis in a Young Man Taking Tirzepatide for Weight Loss
by: Mohammed Fareeduddin Farooqi, FRCP, et al.
Published: (2024-11-01)

Meta-analysis of the efficacy of glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy
by: Ze-jin Liao, et al.
Published: (2024-12-01)

Potential impact of GLP-1 receptor agonists on male fertility: a fable of caution
by: Stefan S. Du Plessis, et al.
Published: (2024-11-01)

Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis
by: Muhammed Shabil, et al.
Published: (2024-11-01)

Glucagon-Like Peptide-1 Receptor Agonist Use is Not Associated With Increased Complications After Total Knee Arthroplasty in Patients With Type-2 Diabetes
by: Kevin Y. Heo, BS, et al.
Published: (2024-12-01)

Long-Acting Glucagon-Like Peptide-1 Receptor Agonist-Induced Rheumatoid Arthritis in a Patient with Type 2 Diabetes Mellitus
by: Koji Kikkawa, et al.
Published: (2021-09-01)

Cardiometabolic Modulation by Semaglutide Contributes to Cardioprotection in Rats with Myocardial Infarction
by: Yan H, et al.
Published: (2024-11-01)

Glucagon-like peptide-1 receptor agonist use is associated with reduced risk of out-of-hospital cardiac arrest in women with type 2 diabetes: A nationwide nested case-control study
by: Talip E. Eroglu, et al.
Published: (2024-12-01)

Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives
by: Kosuke Sawami, et al.
Published: (2024-11-01)

Managing cardiovascular events, hyperglycemia, and obesity in type 2 diabetes through microRNA regulation linked to glucagon-like peptide-1 receptor agonists
by: Xiaolei Miao, et al.
Published: (2025-01-01)

Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study
by: Arunkumar Krishnan, et al.
Published: (2024-12-01)

Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
by: Wael R. Sidrak, et al.
Published: (2024-11-01)

The protective role of GLP-1 in neuro-ophthalmology
by: Sohum Sheth, et al.
Published: (2023-08-01)

Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)
by: Sho Furusawa, et al.
Published: (2024-06-01)

Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease
by: Aaron King, et al.
Published: (2025-03-01)

Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
by: Hayeon Kim, et al.
Published: (2024-10-01)

Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
by: Tian-Yi Ren, et al.
Published: (2024-10-01)

High fructose rewires gut glucose sensing via glucagon-like peptide 2 to impair metabolic regulation in mice
by: Eya Sellami, et al.
Published: (2025-03-01)

Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control studyResearch in context
by: Julien Bezin, et al.
Published: (2025-02-01)

Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus
by: Mijin Kim, et al.
Published: (2025-01-01)

The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
by: Jonathan D. Douros, et al.
Published: (2025-02-01)

Glucagon-like peptide-1 receptor agonists and the risk of erectile dysfunction: a drug target Mendelian randomization study
by: Hongjin An, et al.
Published: (2024-11-01)

Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
by: Chien-Tai Hong, et al.
Published: (2024-11-01)

Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope?
by: Paschalis Karakasis, et al.
Published: (2024-11-01)

Are obese rats influenced by GLP1 and IR through aerobic exercise? A case study
by: Ali Sayyah, et al.
Published: (2016-08-01)

Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta‐Analysis
by: Saixian Shi, et al.
Published: (2025-01-01)

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
by: Richard J. MacIsaac, et al.
Published: (2024-10-01)

Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence
by: Jian‐Yu Jhu, et al.
Published: (2025-02-01)

Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review
by: Yao Wang, et al.
Published: (2024-06-01)

Neuroprotective effects of GLP-1 class drugs in Parkinson’s disease
by: Dongliang Lv, et al.
Published: (2024-12-01)

The Emerging Role of Pharmacotherapy in Obstructive Sleep Apnea
by: Nikhil Jaganathan, et al.
Published: (2024-09-01)

Foundational contributions of Svetlana Mojsov to the GLP-1 field
by: George Barany, et al.
Published: (2024-10-01)